← Eichor
Condition: Advanced Refractory Solid Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Refractory Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced
NA · 1 location(s) · Wuxi People's Hospital · NCT06430502A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 · 3 location(s) · RasCal Therapeutics, Inc. · NCT04678648BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.
Phase 1 · 2 location(s) · Chiome Bioscience Inc. · NCT07016997Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
Phase 1 · 13 location(s) · DeuterOncology · NCT05752552Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Georgiamune Inc · NCT06425926Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT05053971CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Phase 1 · 6 location(s) · Samsung Bioepis Co., Ltd. · NCT07524348BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 · 17 location(s) · SillaJen, Inc. · NCT05768932A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Rabin Medical Center · NCT06940349Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a
Phase 1/Phase 2 · 6 location(s) · Phanes Therapeutics · NCT05431270A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Phase 1 · 9 location(s) · Normunity AccelCo, Inc. · NCT07182149Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unrese
Phase 1 · 4 location(s) · National Cancer Institute (NCI) · NCT05111561A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Phase 1 · 2 location(s) · LaunXP Biomedical Co., Ltd. · NCT06883539First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Phase 1 · 11 location(s) · ImmunoGenesis · NCT06014502A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Heronova Pharmaceuticals · NCT06873555Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05410717TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancrea
Phase 1 · 1 location(s) · University of California, Davis · NCT07189195MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Phase 1 · 1 location(s) · Mayo Clinic · NCT06911008A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 18 location(s) · NiKang Therapeutics, Inc. · NCT07029399AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 · 2 location(s) · University of Southern California · NCT05791448
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.